Antibiotics are the cornerstone of comprehensive cystic fibrosis (CF) therapy, and they are responsible for life expectancy and quality of life benefits that are priceless. Although antibiotic stewardship may appear to be at odds with optimal CF management, there are several potential benefits to antibiotic stewardship in CF. Antimicrobial stewardship teams can help with antibiotic selection, therapeutic medication monitoring, and the promotion of best practices based on evidence-based guidelines by taking a collaborative approach to CF management.

The goal of this review is to present the rationale for antibiotic usage in CF therapy, assess the data supporting existing antibiotic policies, and address the possible role of antibiotic stewardship in CF management.